PROGRESSIVE-LINE − New Implant line
IDS 2019 Highlight
In close collaboration with practicing surgeons, Camlog developed a new implant line to meet the demands for shorter treatment times, earlier prosthetic restoration, and fewer sessions. Hundreds of CAMLOG® PROGRESSIVE-LINE implants have been placed during the last nine months right after the first presentation of this new implant line at the Global Symposium of the Oral Reconstruction Foundation in Rotterdam in April 2018. Since then, surgeons experienced an implant that reliably achieves excellent primary stability in all bone classes and proved the results of in-vitro tests to be reproducible in the clinical routine.
Whereas current concepts in the market for immediacy are realized mainly by niche implants, suitable for specific situations or bone types only, PROGRESSIVE-LINE was developed to be an implant suitable for all indications. The outer geometry of the new implant line − available for both the renown CAMLOG® and CONELOG® connections − was geared to facilitate the implementation of treatment concepts like immediate placement and restoration and has been coupled with highly efficient protocols for the implant bed preparation in all bone types.
Well thought out features of this apically tapered implant prove to be particularly advantageous in soft bone. Threads down to the apex that make PROGRESSIVE-LINE ideal for immediate implantation, while also including a coronal anchorage thread helps to master complex situations in reduced bone height e.g. when performing sinus lift surgery. Additional features encompass a broadened thread height with strongly engaging threads, and flexible drill protocols which allow to adapt the stability according to the needs of the treatment plan. In addition, advanced drill designs offer efficient implant site preparation in dense bone − without requiring additional tools or a tap.
Characters: 3.004 (inkl. spaces)
About BioHorizons and Camlog
BioHorizons and Camlog are leading suppliers of premium dental implant systems, restorative components, a comprehensive line of biologics products and digital solutions. They are committed to developing evidence-based and scientifically proven products, as well as continuous education according to highest standards.
Headquartered in the U.S. and Europe, respectively, BioHorizons and Camlog’s geographic positions allow them to efficiently serve direct subsidiaries in the Americas and Western Europe, as well as their entire distribution network in more than 80 countries around the world.
The companies are part of Henry Schein, Inc., a solutions company for health care professionals powered by a network of people and technology. With more than 18,000 Team Schein Members worldwide, Henry Schein’s network of trusted advisors provides over 1 million customers globally with more than 300 valued solutions that improve operational success and clinical outcomes. The Company’s Business, Clinical, Technology, and Supply Chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites.
For more information, visit www.biohorizons.com, www.camlog.com and www.henryschein.com.
Chief Marketing Officer
CAMLOG media releases may only be used for editorial purposes. Copyrights on the texts and illustrations are owned by CAMLOG Biotechnologies AG, Switzerland, unless a different author is specifically stated. All copyrights entirely remain in force also when texts and images are electronically/manually transferred into an archive.
Illustrations used for editorial purposes must bear the reference "Illustration: CAMLOG". Before publication of a press release, a print approval via the e-mail address below has to be applied for. Publication is free of charge. In cases of print media, we ask you for a voucher copy; in cases of films and/or digital media, we ask you for a notification. Transmission to third parties – including electronically processed form − is prohibited.
Contact: Oliver Ehehalt